Lenskart Q1FY27: consol. PAT triples YoY to ₹228 Cr as int'l ops turn profitable
PAT +273.4% YoY · revenue +43.3% · margins expanding
₹2,714.18 Cr
+43.3% YoY
₹228.43 Cr
+273.4% YoY
8.21%
₹1.28
Consolidated (primary) revenue was ₹2,714.18 Cr, up 43.3% YoY and 7.9% QoQ, with profit after tax (total, including minority interest) of ₹228.43 Cr — up 273.4% YoY and 12.2% QoQ from ₹203.62 Cr. Basic EPS was ₹1.28 versus ₹0.36 a year ago and ₹1.17 last quarter. Standalone PAT of ₹151.48 Cr is far smaller and actually fell 7.4% QoQ despite 3.7% revenue growth — the standalone-vs-consolidated gap (>50%) reflects profitable international operations (Owndays and other overseas units) that sit outside the standalone entity, and readers should treat the consolidated figures, not standalone, as the primary read.
Q1 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
The headline YoY jump is flattered by two factors worth separating from the underlying trend: the year-ago quarter carried a ₹10.39 Cr exceptional impairment loss that depressed the base (adjusted PAT growth ex this one-off is ~219.2%, still large); and the current quarter consolidates two FY26 acquisitions — Meller (sunglasses import/sale, 84.21% stake from August 2025) and Quantduo Technologies (geo-analytics, stake increase September 2025) — that weren't in the year-ago numbers. The company's own proforma statement, prepared specifically for like-for-like comparison, puts adjusted revenue growth at 33.6% (₹2,032.25 Cr proforma base) and adjusted PAT growth at 182.4% (₹80.89 Cr proforma base) — both still strong. The real driver beneath the comps is a genuine turnaround: the International segment swung from a ₹(11.40) Cr loss a year ago to a ₹103.67 Cr profit this quarter (+41.8% QoQ from ₹73.09 Cr), while India segment PBT grew a steadier 53.3% YoY to ₹183.28 Cr. Operating margin (EBITDA basis, excluding other income) expanded to 21.68% from 17.74% YoY and 21.40% QoQ; net margin rose to 8.21% from 3.14% reported (3.68% adjusted for the one-off) YoY and 7.94% QoQ. At the standalone level, employee benefits expense more than doubled sequentially to ₹225.79 Cr from ₹110.63 Cr, the main drag on standalone profitability this quarter.
The stock went into the print at ₹585, up 8.8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 4 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 4-quarter high.
Lenskart provided a strong outlook for FY27, expecting net new store additions to be around FY26 levels and maintaining a long-term steady-state EBITDA pre-Ind AS margin expectation of approximately 25%. The company emphasized prioritizing long-term value creation over short-term linearity, with quarterly margins expec
— This quarter: met
No quarter-specific street consensus for Q1 FY27 could be confirmed via search; broader market commentary cites FY27 full-year PAT growth expectations in the 15-20% range, well below this quarter's pace, but that is an annual, not quarterly, figure and not strictly comparable. Against management's own May 2026 guidance — net store additions around FY26 levels and a long-term steady-state EBITDA (pre-Ind AS) margin near 25%, with quarterly margins expected to swing on store-opening phasing and seasonality — this quarter's 21.68% OPM is progressing toward that target (+394 bps YoY) but hasn't reached it, consistent with management's own framing that short-term linearity isn't the goal; call it on-track rather than a beat. Corporate activity this quarter centered on international manufacturing control: the board approved raising the stake in China JV Baofeng Framekart Technology (which supplies over 30% of Group eyewear production) from 51% to 70% for ~RMB 7.5 Mn, alongside new step-down subsidiaries in South Korea (OWNDAYS Korea) and China (Wenzhou Framekart Trade), plus a separately-reported JV with Mingfeng Glassesworld for metal-frame manufacturing — all consistent with the prior call's backward-integration and long-term-value language. The board also carried forward the previously approved merger of two wholly-owned subsidiaries (Dealskart Online Services, Lenskart Eyetech) into the parent, still pending NCLT approval with no P&L impact yet, and allotted 5,85,561 ESOP shares. No standalone management press release was available in the context to check against these numbers.
W1
OPM at 21.68% (+394 bps YoY, +28 bps QoQ) is still ~330 bps below management's long-term steady-state EBITDA (pre-Ind AS) margin target of ~25% — watch the pace of convergence next quarter
W2
Standalone employee benefits expense more than doubled QoQ to ₹225.79 Cr from ₹110.63 Cr — watch whether Q2 FY27 reverts or this is a new run-rate
W3
International segment PBT turnaround (₹103.67 Cr vs a ₹(11.40) Cr loss a year ago) — watch whether the +41.8% QoQ pace holds as OWNDAYS Korea and the Framekart stake increase (51%→70%) integrate
Market builder shows cracks in growth
Lenskart posted aggressive store additions (455 in 9 months) and delivered eye-test market creation (63L, +42.7% YoY). But blended EBITDA margin at 13.3% is half the 25% guidance — and QoQ revenue growth slowed to +7.9%, signalling execution risk on unit economics at scale.
Lenskart delivered a quarter that looks good on the surface — aggressive store additions (455 in 9 months, the fastest pace ever), eye-test market creation (63 lakh in Q1, up 42.7% YoY), and international profitability achieved (10.6% EBITDA margin for the first time). But beneath these headlines sits a structural tension: blended EBITDA margin of 13.3% is half the 25% long-term guidance, and management offered no quantified path to recovery. QoQ revenue growth (+7.9%) also slowed sharply, raising questions about whether the TAM expansion narrative is hitting headwinds faster than expected.
The margin gap that defines the quarter
13.3%
India 15.4% + Intl 10.6%
~25%
Prior guidance, reaffirmed on call
11.7 pp
Nearly half unmet
~2,900
116 net added in Q1
16 net added
Slow relative to revenue growth
This is not a one-quarter miss explained by near-term investments (store openings, remote optometry rollout, AI R&D). The gap between delivered and guided margin is so large that it signals either: (1) management's long-term target is aspirational and unlikely, or (2) unit economics at scale are worse than private-era performance. Management's framing — that "quarterly variance is expected due to store opening phasing, seasonality, and strategic investments" — is a hedge that sidesteps the core question: when and how does margin recover?
What the profit breakdown shows
India segment is pulling its weight (15.4% margin, revenue up 30.7% YoY). International is improving fast — crossing 10% margin for the first time is a real upgrade. But the blended 13.3% reflects the drag of rapid Tier-2 store expansion in India (lower mature store density) and international still scaling profitability. Cash generation is strong (₹297 Cr operating CF, 82% EBITDA-to-cash conversion), suggesting the profit is real, not accounting-driven. But at this margin rate, Lenskart is running at half the returns it needs to justify the long-term model.
Management's claims vs. what holds up
Revenue grew 34% YoY; PAT grew 182%
OverstatedYoY figures rest on private FY26 proforma (no public prior-year comparatives; first listing in Nov 2025). QoQ shows only +7.9% revenue, +12.2% PAT — much slower.
A third more revenue has doubled post-rent EBITDA and nearly tripled PAT
ContradictedBlended EBITDA margin 13.3% falls well short of 25% guidance. Claim appears to reference prior proforma levels, not absolute growth.
India SSSG 18.3%; same pin code growth 24%
SupportedBoth figures confirmed in call. Store density rising 1.5→1.6/pin code, yet SSSG accelerating YoY — demand-led, not cannibalizing.
Intl EBITDA margin crossed 10% for first time (10.6%)
SupportedIntl EBITDA ₹127 Cr on ₹1,203 Cr revenue = 10.6%. Prior year ~4.8%. Profitability thesis confirmed.
Eye tests grew 42.7% to 63 lakh; remote optometry in 786 stores (vs 168 end-FY25)
SupportedFigures stated. Remote optometry rollout 168→786 is ~4.7x in 9 months. Eye test growth +42.7% backed by majority first-time customer mix.
₹500 Hustlr Club now profitable; ₹30k+ lenses ₹250 Cr annualized
SupportedManagement confirmed unit economics work at ₹500 before launch. ₹250 Cr is only super-premium (₹30k+ segment), narrowly claimed but accurate.
What changed on this call
International profitability confirmed (10.6% margin; was loss-making prior year). No longer a question mark.
Margin guidance implicitly reset to flexibility ("quarterly variance expected"). No formal FY27 revenue/margin target. Prior 25% ceiling now hedged.
Talent constraint surfaced as #1 bottleneck (flagged above real estate, product, tech). Tier-2 hiring capacity is now the limiting factor for scale.
₹500 Hustlr Club viability claimed profitable (was aspirational). Largest-ever cohort onboarded in Q1; democratization moving from theory to live.
The bull-bear ledger
TAM is large and low-penetration (35% in India; 78→94 Cr vision-correction needs by FY30). Runway for 10,000+ stores.
Store density model proven (SSSG held 18.3% YoY despite 1.5→1.6 stores/pin code rise). Demand-accretive densification, not cannibalization.
Eye tests market-creating (63L in Q1, +42.7% YoY, majority first-time customers). Funnel expansion, not share shift.
International profitability achieved (10.6% margin, crossing 10% for first time). Segment de-risked.
ROCE recovered to 23% (vs 14% FY25) despite 455 store adds in 9m. Capital discipline evident.
Blended EBITDA margin 13.3% vs 25% target (half). No clear recovery path articulated.
QoQ revenue growth slowing (+7.9%) despite fastest store additions ever. TAM narrative may be hitting headwinds faster than expected.
Talent constraint flagged as #1 bottleneck. Tier-2 store hiring, training, retention capacity unclear.
Remote optometry accuracy unvalidated by independent audit (27% of stores; monitored via internal Tango Eye + exchange rates). Regulatory risk if questioned.
International acceleration delayed ("maybe not this year"). Tech integration bottleneck; margin leverage deferred to FY28+.
NPS dipped in Q1 (policy confusion resolved). Service quality risk as network expands into Tier-2-3 with lower-experience staff.
Ranked risks for a holder
Margin sustainability (13.3% vs 25% target)
HighGap of 11.7 pp is not explained by near-term investments. If margins do not recover to 18%+ by FY28, the unit economics thesis breaks and valuation resets lower 25–30%.
Talent & execution (Tier-2 hiring/training bottleneck)
HighFlagged as #1 constraint. If Tier-2 store pace cannot accelerate due to staffing, revenue growth stalls and the 10,000-store TAM case collapses.
Store unit economics/cannibalization at scale
MediumDensity rising (1.5→1.6 stores/pin code). At 10,000 stores (3.5x scale), older cohorts could face SSSG compression. Bangalore (20% SSSG despite density rise) is only one market proof.
Remote optometry accuracy (unvalidated)
Medium27% of stores now using remote eye tests (786 of 2,900). Accuracy monitored via internal systems only. If questioned by regulator or customers, brand and SSSG at risk.
International acceleration delay
MediumTech integration "maybe not this year." If acceleration pushed to FY28-29, margin leverage from international scale deferred; blended margins stay under 15% longer.
Competitive response (D2C, traditional opticians)
MediumLenskart's moat (scale, omnichannel, data) is strong but not insurmountable. If Warby Parker-style D2C emerges or traditional opticians digitize, pricing power erodes.
How the street is positioned
Post-result price action: The stock popped +1.78% on day 1 and extended to +3.61% by day 3, holding gains — the market's own verdict that results were digestible. At ₹639.6, the stock sits at -0.83% from its all-time high, well above the 20-day SMA (₹580.68) and 50-day SMA (₹546.88), confirming an intact uptrend. RSI at 84.4 signals overbought conditions — there is little room for disappointment without sharp pullback.
Institutional flows are massive: FII ownership jumped 8.5 percentage points to 12.76% (from 4.26% in Q4 FY26). Domestic institutional investors (DII) added 8.09pp to 23.57%. This is strong conviction from sophisticated capital. Promoter holding stable at ~17.5%; no insider selling flagged.
Block deal activity tells a bullish story: Large institutional buyers (Goldman Sachs, HDFC Life, ICICI Prudential, Kotak Life) accumulated shares at ₹490 in bulk deals. Current price ₹639.6 is a 30% premium to those block prices, suggesting institutions are holding for conviction. No large seller appears; the sole block sale was 4 Cr shares from Platinum Jasmine Trust (portfolio rebalancing, not insider dumping).
The street's positioning reconciled with fundamentals: Institutions are buying the market-creation narrative (TAM expansion, eye tests, international profitability) and willing to overlook the margin gap as near-term execution noise. But the stock's overbought setup (RSI 84.4, near ATH) and the margin miss suggest the bar for next quarter is very high. If Q2 EBITDA margin does not improve to 14%+, or if talent constraints visibly limit store acceleration, the post-result pop will fade quickly. Current positioning leaves no margin of safety.
The debate
What to watch next
1 · Q2 FY27 SSSG resilience and margin inflection (Sep 2026)
Q2 is typically weaker seasonally (post-monsoon), but it's the acid test. If SSSG holds 15%+ and EBITDA margin improves to 14%+, the thesis survives. If either misses, guidance credibility shatters.
2 · International tech integration completion and acceleration announcement (H2 FY27)
Management hedged FY27 acceleration timing to "coming years, maybe not this year." If GeoIQ mapping is live and dual-brand strategy (Singapore, Thailand) proves scalable, an FY28 acceleration announcement would unlock long-term margin leverage.
3 · FY28 margin guidance reset or confirmation (May 2027)
The credibility hinge. Management must either reset 25% target to realistic 18–20% or provide quantified path ("25% by FY29, with these milestones"). Vague guidance triggers re-rating lower.
The single number to track from here
Blended EBITDA margin. If it reaches 15%+ in Q2 FY27 and 16%+ by FY28 Q1, the 25% aspiration is plausible and the stock deserves premium valuation. If margins stall at 13–14%, the gap to 25% becomes structural — unit economics are broken at scale — and valuation resets lower by 25–30%.
Lenskart is not a flawed company; it is a well-executed growth story. Market creation (eye tests, remote optometry, Tier-2 densification) is real. International profitability is a genuine upgrade. But the margin gap (13.3% vs 25%) signals execution risk on the long-term model, and the overbought technicals leave no safety margin. This quarter shows steady operational excellence — not a step-change. Hold existing positions; new buyers should wait for a pullback to ₹540–575 to de-risk the setup.
Margin leverage test — can growth + tech efficiency power 40%+ PAT gains?
Lenskart enters Q1 FY27 on a strong run: FY26 saw revenue +32%, adjusted PAT +148%, and store expansion accelerating. The Street expects continued momentum on digitization, unit economics, and footprint. Watch whether margin leverage persists amid JV integration and competitive pricing.
What to expect
~₹23k–24k Cr
~25–28% YoY growth; trajectory implies ₹92–96k for full FY27 if steady.
~18–20%
FY26 run-rate; watch for store density gains and tech-driven cost leverage.
~₹1.4k–1.6k Cr
Margin expansion only if operating leverage offsets higher capex on store rollout.
500+
Company guided for 5.6k+ by FY30; Q1 should show sequential store adds.
Strong quarter: Revenue exceeds ₹24k Cr, PAT beats ₹1.6k Cr, and gross/EBITDA margins hold above 20%. Signalling tech-driven efficiency gains and store unit economics on track. Weak quarter: Revenue misses ₹23k Cr, PAT below ₹1.4k Cr, or margin compression from competitive pricing or store ramp costs. Would suggest either a slowdown in like-for-like sales or JV/capex headwinds.
On track?
Lenskart is executing on a multi-year playbook: FY26 delivered ₹90k Cr revenue (+32%), ₹5.3k Cr adjusted PAT (+148%), and ₹23.5k Cr Q4 revenue alone. A mid-20s percent Q1 print would align with that trajectory. The company has signalled no major business headwinds — all filings point to accelerating store rollout (toward 5.6k by FY30), digital penetration rising, and unit-level margins expanding through automation. A 30%+ PAT growth would confirm the thesis; anything below 20% YoY invites questions on mix, competition, or capex intensity.
What the Street says
Since last quarter
1 · Metal-frame JV is live (July 30, 2026)
Lenskart incorporated Lenskart Metalframes Private Limited with China-based Mingfeng Glassesworld. Strategic move to localize metal-frame production and reduce import costs. Early-stage in Q1; contribution likely under 5% of earnings, but symbolic of backward integration.
2 · Subsidiary merger (consolidation)
Board approved merger of Dealskart Online Services and Lenskart Eyetech into the parent (July 2, 2026). Streamlines reporting and centralizes product/platform strategy. Minimal accounting impact but signals operational tightening.
3 · OWNDAYS stake increase (Japan play)
Lenskart acquired remaining 3% stake in Quantduo Technologies (June 9) and approved additional OWNDAYS shareholding (May 20). International diversification, but offshore earnings still ~5–10% of group. Watch guidance on FY27 geography mix.
4 · Promoter/insider activity
MacRitchie Investments sold 2.05% stake (July 10 @ ₹490). Platinum Jasmine Trust sold 2.30% (June 12 @ ₹490). Routine portfolio churning at ~15% discounts to current price; no red flag, but shows SE Asia PE exits. FII up 40bps to 4.26% in latest quarter; DII stable. Healthy institutional interest.
5 · AGM and AGM notice (Aug 19, 2026)
18th AGM on Aug 19; FY26 annual report already circulated. No contentious shareholder proposals reported. Expect dividend confirmation and routine board governance items.
Three things to watch on result day
1 · Like-for-like store growth & comp-store sales
Is the LFL growth in low-to-mid 20s% or accelerating into the 30s? Store productivity (sales per location) is the true proof of unit economics. A slowdown here would suggest urban saturation or pricing pressure.
2 · Gross margin and EBITDA run-rate
Can gross margin stay above 60% and EBITDA margin above 18–20%? Any compression here invites mix/pricing concerns. Conversely, a 100bp+ expansion would signal the tech-efficiency flywheel is accelerating.
3 · FY27 guidance and JV/capex outlook
Will management reiterate full-year revenue/PAT guidance and provide a view on the metal-frame JV contribution & cash capex for store expansion? Quiet on this front = either conservative posture or caution on second-half visibility.
Lenskart is at an inflection: FY26 proved that digital + scale + tech can drive 30%+ profit growth. Q1 FY27 is the test of whether that's a one-year sprint or a multi-year stride. The Street is betting on the latter — hence the Buy consensus and targets north of ₹600. A strong Q1 (revenue ₹24k+ Cr, PAT ₹1.6k+ Cr, margin expansion) would re-affirm the thesis and likely push the stock toward ₹625–650. A soft Q1 (revenue ₹22.5k Cr or less, margin squeeze) would trigger a debate on capex vs. profitability and invite a re-rate down to ₹540–560.
Watch revenue growth (target ₹24k+), margin integrity (EBITDA >19%), and management's tone on second-half demand and FY27 guidance. The JV is window-dressing for now; the real story is unit economics at 5.6k stores and whether automation keeps pace with store density.
Solid operator, TAM narrative compelling, but execution risk on margin sustainability
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
No prior formal guidance given (first public quarter). Long-term 25% EBITDA margin target stated but unmet (13.3% delivered). Store model and premiumization strategy backed by data; international profitability achieved.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Lenskart is building a defensible omnichannel retailer with a large TAM (78→94Cr Indians needing vision correction by FY30) and proven store density model. International profitability achieved (10.6% EBITDA margin). However, delivered margin of 13.3% is half the 25% long-term target, and QoQ growth (+7.9% revenue) is moderating despite aggressive store additions (455 in 9m). Talent constraint and remote optometry accuracy (unvalidated) are material risks. The multi-year vision is compelling, but execution risk is high on margin recovery and unit economics at scale.
₹2714.2 Cr
Revenue · +null% YoY₹228.4 Cr
Reported PAT · +null% YoYFlat
Margins · vs guidance: UnverifiedDid the claims hold up?
Revenue grew 34% year-on-year; PAT grew 182%
OVERSTATEDYoY figures unverified for public reporting (first listed quarter Nov 2025). Claimed vs. prior proforma private FY26 Q1. QoQ shows revenue +7.9%, PAT +12.2%—much slower.
A third more revenue has doubled post-rent EBITDA and nearly tripled PAT
MISSConsolidated EBITDA (India ₹236Cr + Int'l ₹127Cr) = ₹363Cr. Blended margin 13.3%. Falls well short of 25% steady-state guidance. Claim appears to reference proforma comparisons.
India same-store sales growth 18.3%, same pin code growth 24%
METBoth figures stated in call. Net new stores 116, yet SSSG held firm, proving densification demand-accretive. Claim supported by data.
International EBITDA margin crossed 10% for first time, is now 10.6%
METIntl EBITDA ₹127Cr on ₹1,203Cr revenue = 10.6%. Prior year was ₹42Cr on ₹873Cr = 4.8% approx. Profitability confirmed.
Eye tests grew 42.7% to 63 lakh in India; remote optometry in 786 stores (vs 168 end-FY25)
METFigures stated. Remote optometry rollout from 168 to 786 is ~4.7x in 9 months. Eye test growth and remote expansion both material.
Owndays premium at ₹1,500 Cr sales; ₹30k+ lenses ₹250 Cr annually
METPeyush clarified ₹250Cr is ONLY ₹30k+ segment, not total progressives. ₹1,500 Cr is Owndays premium segment, not all Owndays. Both are subsegments, claimed correctly but narrowly.
Earnings quality
What changed since the last call
International profitability confirmed
UpgradeQ1 margin 10.6% (₹127 Cr EBITDA on ₹1,203 Cr revenue), vs 4.8% prior year. Profitability thesis no longer questioned. Remains below India 15.4%, but crossing 10% is material upgrade.
Margin guidance implicit reset
Downgrade25% steady-state target maintained but 13.3% blended delivered. Management hedged: 'quarterly variance expected'. No formal FY27 guide, but tone shifted to flexibility vs. prior leverage narrative.
Talent constraint surfaced
NewPeyush flagged talent/culture/speed as #1 bottleneck (above real estate, product). Tier-2 expansion requires local hiring, training. AI/data engineering talent scarce. Not previously prominent risk.
₹500 Hustlr Club viability claimed
UpgradeManagement stated 'we can do it profitably' now (previously cost-prohibitive). Largest ever cohort onboarded in Q1. Democratization strategy moving from aspirational to live.
The Q&A
Q&A was substantive. Analysts pressed on SSSG moderation (held, no decline), international acceleration timeline (hedged to 'coming years'), margin sustainability (flexible narrative), and ₹500 cannibalization risk (tech + branding mitigation). Peyush answered directly most times; occasional philosophical framing (market-creation ethos) when hard numbers unavailable. No defensive tone, but clear comfort with near-term messiness.
Store age cohort stress — Avi Mehta, Morgan Stanley
AnsweredPenetration only 35%, myopia/progressives gaining share, eye tests top funnel. Offset currency via in-house mfg, vendor discounts, backward integration. SSSG held 18% despite density increase.
Tier-2 expansion bottleneck — Vivek M, Jefferies
AnsweredTier-2 needs logistics/talent muscle; remote optometry was unlock. Premium = ₹3.5k+ lenses, ₹5k+ frames (Owndays, Meller). ₹500 = India mfg, logistics optimization, omnichannel CAC efficiency.
Key metrics moderation — Tejas Shah, Avendus
AnsweredNPS dip was policy confusion, bounced back. SSG accelerating YoY (18% vs 16%). Talent is #1 constraint; need data/AI engineers. Remote optometry and self-eye test are unlocks.
Progressive lens opportunity — Amit Sachdeva, UBS
Answered₹250 Cr is only super-premium, not all progressives. Playbook = eye test + marking + AI design. Brand via authenticity (Virat in Meller ₹50, Blackpink), not above-the-line spend.
International leverage, acceleration — Garima Mishra, Kotak
AnsweredFollowing India playbook (100→300→450): focus eye tests, capex rationalization, margin recovery first. Flywheel unlocks acceleration; Japan getting there; SSG headroom in intl markets.
Eye test conversion funnel — Percy Panthaki, IIFL
PartialMajority convert; first-time customers take longer. Unlikely to forecast FY27 full-year margin vs quarter; seasonality in Q1 (sunglasses), YoY improving overall.
International store potential model — Arnab Mitra, Nomura
AnsweredCloser to acceleration, tech integration ongoing. Eyewear is neighborhood model everywhere. GeoIQ now mapping intl; pin codes are shareholder storytelling, actual model data-driven.
Remote eye test accuracy — Devanshu Bansal, Emkay
AnsweredRemote more consistent than unmonitored optometrist. Use Tango Eye (computer vision) for process scoring + exchange data. Prevent cannibalization via omnichannel (face scan app, brand house).
₹500 margin impact — Aditya Soman, CLSA
AnsweredUnit economics work before launch. Lower price points more margin accretive than higher. Rodenstock = manufacturing + licensing (raw materials + design from brand, made in India).
Owndays vs Lenskart strategy — Amit Purohit, Elara
AnsweredStrategy by market. Singapore dual-brand success (both coexist, serve different segments). Thailand also dual-brand working. Japan different strategy. Learning as we go.
Guidance
No formal FY27 revenue target stated
LowCEO framed as market-creation play; store additions 455 in 9m, suggesting base case 600+ net adds/year. Implies revenue CAGR but unquantified.
Long-term ~25% steady-state EBITDA pre-Ind AS margin (aspirational)
LowCurrent 13.3% blended; management hedged: quarterly variance expected due to store opening phasing, seasonality, strategic investments. No near-term lift timeline.
Store capex ₹75Cr (Q1); plant capex ₹132Cr (Hyderabad facility, ongoing)
MediumHyderabad facility supports backward integration (frames, lenses). Capex intensity moderate (~4% of revenue). No full-year guidance.
Risks the call surfaced
Margin sustainability
HighBlended EBITDA margin 13.3% (India 15.4%, Int'l 10.6%) is half the long-term 25% guidance. Gap not explained by near-term investments alone. If margins do not recover to 20%+ by FY28, thesis breaks.
Store unit economics
Medium455 net stores added in 9 months; density 1.5→1.6/pin code. SSSG held 18.3% YoY, but older cohorts may face incremental pressure. At 10,000 stores (3.5x scale), cannibalization could emerge.
Talent & execution
HighPeyush flagged talent/culture/speed as #1 constraint (above real estate, product). Tier-2 expansion requires local hiring, training, retention. Data/AI talent scarce. Risk if hiring cannot keep pace with store expansion.
Remote optometry accuracy
MediumRemote eye tests now in 786 stores (27% of network), driving volume +42.7%. Accuracy monitored via Tango Eye (process scoring) + customer exchange rates, not independent audits. Risk if accuracy later questioned or regulator scrutinizes.
NPS dip & service quality
LowNPS moderated in Q1 due to social media policy miscommunication. Resolved per Peyush, but signals execution risk on service quality as Tier-2 expansion accelerates. Service consistency across 2,900+ stores under pressure.
International acceleration delay
MediumOnly 16 net stores added internationally in Q1 despite 38% revenue growth (SSG doing heavy lifting). Tech integration 'maybe not this year.' If delayed, international remains low-store-count, high-SSG business. Margin leverage from scale deferred.
Competitive response
MediumLenskart's moat is scale, omnichannel, data (GeoIQ, Tango), and acquired brands (Owndays, Meller). Traditional opticians have installed base and relationships. Online D2C (Warby Parker-style) could emerge. If competitor copies remote optometry + AI eye test, competitive moat erodes.
Management
Score 7/10. Clear on strategy (market-creation, TAM expansion, omnichannel playbook). Specific on store metrics, SSSG, eye test numbers. Hedges on margins (quarterly variance), international timing (tech integration), ₹500 cannibalization (tech + branding mitigation not hard caps). Transparent on talent as bottleneck. Delivered: 455 net stores in 9m (fastest in history), eye tests +42.7%, SSSG 18.3%, international profitability achieved (10.6%). Missed: margin recovery (13.3% vs 25% target), modest QoQ growth (+7.9% revenue). Mixed track record, one quarter public.
1 · Q2 FY27 (Sep 2026)
Eye test growth sustenance; Q2 typically weaker (post-monsoon). SSSG resilience as store density rises.
2 · H2 FY27 (Oct-Mar 2027)
International tech integration completion; acceleration announcement for FY28 store additions. Meller and Owndays brand momentum.
3 · FY28 guidance (May 2027)
Management resets margin target or confirms 25% steady-state path. Critical credibility inflection.
The multi-year vision is compelling, but execution risk is high on margin recovery and unit economics at scale.